)
SACHRP Recommendations
January 10, 2013 SACHRP Letter to the HHS Secretary
January 10, 2013
The Honorable Kathleen Sebelius
Secretary of Health and Human Services
200 Independence Avenue, S.W.
Washington, D.C. 20201
Recommendation Letter
Dear Ms. Sebelius:
On behalf of the Secretary’s Advisory Committee on Human Research Protections (SACHRP), I respectfully submit for your consideration recommendations relevant to the Department of Health and Human Services (HHS) human subjects protection regulations at 45 CFR part 46. These recommendations, stemming from the SACHRP Subcommittee on Harmonization and Subpart A Subcommittee, were passed by SACHRP at their October 2012 meeting.
On behalf of the Secretary’s Advisory Committee on Human Research Protections (SACHRP), I respectfully submit for your consideration recommendations relevant to the Department of Health and Human Services (HHS) human subjects protection regulations at 45 CFR part 46. These recommendations, stemming from the SACHRP Subcommittee on Harmonization and Subpart A Subcommittee, were passed by SACHRP at their October 2012 meeting.
Recommendations from the Subcommittee on Harmonization
On October 28, 2009, SACHRP approved a recommendation establishing a Subcommittee on Harmonization (SOH). SACHRP’s charge to this subcommittee was to identify and prioritize areas in which regulations and/or guidelines for human subjects research adopted by various agencies or offices within HHS would benefit from harmonization, consistency, clarity, simplification and/or coordination. The Subcommittee will develop recommendations for consideration and possible adoption by SACHRP, to harmonize and simplify these guidelines and regulations. The goal of this subcommittee effort is to reduce unnecessary burdens on research efforts, thus resulting in better allocation of research resources and promoting the safety and welfare of human subjects.
SACHRP approved the following recommendations and comment from this subcommittee on October 10, 2012:
IRB Knowledge of Local Context (Attachment A)
Commentary on OHRP and FDA Draft Guidance Documents on Transfer of Research to New Institutions (Attachment B)
SACHRP approved the following recommendations and comment from this subcommittee on October 10, 2012:
IRB Knowledge of Local Context (Attachment A)
Commentary on OHRP and FDA Draft Guidance Documents on Transfer of Research to New Institutions (Attachment B)
Recommendations from the Subpart A Subcommittee
On October 5, 2004, SACHRP approved a recommendation establishing a Subpart A Subcommittee (SAS). SACHRP’s charge to this subcommittee was to review and assess all provisions of subpart A of 45 CFR part 46 (HHS’ codification of the Federal Policy for the Protection of Human Subjects, also known as the Common Rule) and relevant Office for Human Research Protections (OHRP) guidance documents, and based on this review and ongoing assessment, to develop recommendations for consideration by SACHRP in three categories: (1) recommendations on interpretation of subpart A provisions; (2) recommendations for development of new, or modification of existing, OHRP guidance; and (3) recommendations for possible revision of subpart A.
The goals of this review and assessment of subpart A of 45 CFR part 46 are threefold: (1) to enhance the protection of human subjects; (2) to reduce, where possible, regulatory burdens that do not contribute to the protection of subjects in a meaningful way; and (3) to promote scientifically and ethically valid research. To that end, SACHRP approved the following recommendations and comment from this subcommittee on October 9 and 10, 2012:
Recommendations on Investigator Responsibilities (Attachment C)
Recommendations on Informed Consent and Waiver of Consent (Attachment D)
On behalf of SACHRP, I would like to thank you for your consideration of this report. The committee, the Subpart A Subcommittee and the Subcommittee on Harmonization have been actively working in pursuit of their charges, and we look forward to continuing this work to enhance human subjects protections for the benefit of all Americans.
The goals of this review and assessment of subpart A of 45 CFR part 46 are threefold: (1) to enhance the protection of human subjects; (2) to reduce, where possible, regulatory burdens that do not contribute to the protection of subjects in a meaningful way; and (3) to promote scientifically and ethically valid research. To that end, SACHRP approved the following recommendations and comment from this subcommittee on October 9 and 10, 2012:
Recommendations on Investigator Responsibilities (Attachment C)
Recommendations on Informed Consent and Waiver of Consent (Attachment D)
On behalf of SACHRP, I would like to thank you for your consideration of this report. The committee, the Subpart A Subcommittee and the Subcommittee on Harmonization have been actively working in pursuit of their charges, and we look forward to continuing this work to enhance human subjects protections for the benefit of all Americans.
Sincerely,
/s/
Barbara E. Bierer, M.D.Former Chair, Secretary’s Advisory Committeeon Human Research Protections(SACHRP)
cc: Jerry Menikoff, M.D., J.D., Executive Secretary, SACHRPJulia Gorey, J.D., Executive Director, SACHRP
Barbara E. Bierer, M.D.Former Chair, Secretary’s Advisory Committeeon Human Research Protections(SACHRP)
cc: Jerry Menikoff, M.D., J.D., Executive Secretary, SACHRPJulia Gorey, J.D., Executive Director, SACHRP
Meeting Members:
Barbara Bierer, M.D.ChairHarvard Medical SchoolBrigham and Women’s HospitalBoston, Massachusetts
Albert J. Allen, M.D., PhD.Eli Lilly & Co.Indianapolis, Indiana
Carl H. Coleman, J.D.Seton Hall Law SchoolNewark, New Jersey
Gary Chadwick, Pharm. D., MPH, C.I.P.University of RochesterRochester, New York
Thomas Eissenberg, Ph.D.Virginia Commonwealth UniversityRichmond, Virginia
David G. Forster, J.D., M.A., C.I.P.Western International Review BoardOlympia, Washington
Albert J. Allen, M.D., PhD.Eli Lilly & Co.Indianapolis, Indiana
Carl H. Coleman, J.D.Seton Hall Law SchoolNewark, New Jersey
Gary Chadwick, Pharm. D., MPH, C.I.P.University of RochesterRochester, New York
Thomas Eissenberg, Ph.D.Virginia Commonwealth UniversityRichmond, Virginia
David G. Forster, J.D., M.A., C.I.P.Western International Review BoardOlympia, Washington
Steven Joffe, M.D., MPHDana-Farber Cancer InstituteBoston, Massachusetts
Susan Krivacic, M.P. Aff.PBG Consulting LLCAustin, Texas
Suzanne M. Rivera, Ph.D., M.S.W.Case Western Reserve UniversityCleveland, Ohio
Lainie F. Ross, M.D., PhD.University of ChicagoChicago, Illinois
Stephen O. Sodeke, Ph.D., M.A.Tuskegee UniversityTuskegee, Alabama
Jerry Menikoff, M.D., J.D.Executive Secretary
Julia Gorey, J.D.Executive Director
Susan Krivacic, M.P. Aff.PBG Consulting LLCAustin, Texas
Suzanne M. Rivera, Ph.D., M.S.W.Case Western Reserve UniversityCleveland, Ohio
Lainie F. Ross, M.D., PhD.University of ChicagoChicago, Illinois
Stephen O. Sodeke, Ph.D., M.A.Tuskegee UniversityTuskegee, Alabama
Jerry Menikoff, M.D., J.D.Executive Secretary
Julia Gorey, J.D.Executive Director
Related Recommendations
Attachment D: Informed Consent and Waiver of ConsentAttachment C: Investigator ResponsibilitiesAttachment B: Comments on OHRP and FDA Draft Guidance Documents Regarding IRB TransfersAttachment A: Consideration of Local Context with Respect to Increasing Use of Single IRB Review
Content created by Office for Human Research Protections (OHRP)Content last reviewed January 10, 2013